Final rule 2026-12443
Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The Food and Drug Administration (FDA) is classifying the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the simple in vitro diagnostic device for the detection of secreted proteins from Bacillus species (spp.) in human clinical samples. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Source-supplied record
Document details
- Document number
- 2026-12443
- Published
- Jun 22, 2026
- Effective
- Jun 22, 2026
- Comments close
- Not supplied
- Federal Register citation
- 91 FR 36976
Docket identifiers
- Docket No. FDA-2026-N-6239
CFR references
- Title 21, part 866